Cangrelor Injection, Powder, Lyophilized, For Solution
Product Images NDC 68083-412

Product Visual Gallery

This gallery contains 7 technical images submitted to the FDA as part of the official labeling for Cangrelor (NDC 68083-412). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Gland Pharma Limited, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Cangrelor-spl-carton-label (Cangrelor Spl Carton Label)

Packaging label for Cangrelor Injection 50 mg per vial, a lyophilized powder for solution intended for intravenous use. The label indicates a package of 10 single-dose vials. Manufactured by Gland Pharma Limited, Hyderabad, India. Includes storage and reconstitution instructions and a barcode.*

FDA Label Image

Cangrelor-spl-container-label (Cangrelor Spl Container Label)

Label for Cangrelor Injection, powder for solution, 50 mg per vial, single-dose vial for intravenous use only. Manufactured by Gland Pharma Limited. The label includes storage instructions, dosage information, and a barcode.*

FDA Label Image

Cangrelor-spl-figure-1 (Cangrelor Spl Figure 1)

A forest plot comparing outcomes between cangrelor (50 mg) and clopidogrel across various subgroups including age, gender, race, weight, patient presentation, prior TIA/stroke, and diabetes. The plot shows odds ratios with 95% confidence intervals, with markers for each subgroup indicating whether cangrelor or clopidogrel performed better.*

FDA Label Image

Cangrelor-spl-figure-2 (Cangrelor Spl Figure 2)

This is a line graph titled 'Cangrelor PD Characteristics' showing plasma concentration (ng/mL) and platelet aggregation percentage over time (minutes). The graph includes data for a bolus and infusion dosing regimen with a recovery time highlighted, illustrating pharmacokinetic (PK) and pharmacodynamic (PD) responses of Cangrelor.*

FDA Label Image

Cangrelor-spl-figure-3 (Cangrelor Spl Figure 3)

A line graph depicting the mean inhibition of 20 µM ADP-induced platelet aggregation (IPA) over time in hours. It compares the effects of Cangrelor infusion followed by transition to three oral P2Y12 platelet inhibitors: Clopidogrel (600 mg), Prasugrel (60 mg), and Ticagrelor (180 mg). The y-axis shows IPA percentage, and the x-axis shows time in hours, highlighting changes in platelet inhibition during and after Cangrelor infusion.*

FDA Label Image

Cangrelor-spl-figure-4 (Cangrelor Spl Figure 4)

A forest plot graph titled 'CHAMPION PHOENIX Study: Primary Efficacy Endpoint by Subgroup (mITT Population)' comparing efficacy between Cangrelor and Clopidogrel across various patient subgroups. It displays odds ratios with 95% confidence intervals for factors such as age, gender, race, weight, patient presentation, prior TIA/stroke, and diabetes status. The horizontal axis ranges from 0.1 to 10, marked as 'Cangrelor better' on the left and 'Clopidogrel better' on the right.*

FDA Label Image

Cangrelor-spl-structure (Cangrelor Spl Structure)

Chemical structure of Cangrelor, showing its molecular components including phosphate groups, sugar moiety, nitrogen-containing rings, and sulfur-containing side chains.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.